Efficacy of Platelet-rich Plasma Injection Compare With Corticosteroid in Pes Anserinus Pain Syndrome
Launched by RAMATHIBODI HOSPITAL · Jun 10, 2024
Trial Information
Current as of July 03, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different types of injections to treat a condition called pes anserinus bursitis, which causes pain on the inner side of the knee. The researchers want to find out if an injection made from a patient’s own blood, called platelet-rich plasma (PRP), is better at reducing pain than a corticosteroid injection, which is a common anti-inflammatory treatment. Participants will be divided into two groups: one group will receive the PRP injection, and the other group will receive the corticosteroid injection. The effectiveness of each treatment will be checked at several points over 24 weeks.
To join the study, participants must be at least 18 years old and diagnosed with pes anserinus pain syndrome. However, there are some exclusions; for example, those with infections, certain medical conditions like rheumatoid arthritis, or who are pregnant cannot participate. Throughout the trial, participants will report their pain levels and function in their daily activities at specific times. This trial is not yet recruiting, but it aims to provide valuable information about the best way to relieve pain for people with this condition.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Over 18 years old
- • Patients diagnosed with Pes Anserine Pain Syndrome
- • Patients willing to participate in the research project by signing a consent form
- Exclusion Criteria:
- • Patients with a localized knee infection or a disseminated infection within the past 3 months
- • Patients with thyroid disorders, rheumatoid arthritis, or other types of knee arthritis
- • Patients with abnormal blood coagulation or thrombocytopenia
- • Patients who are pregnant
- • Patients with any type of cancer
- • Patients who cannot follow up with treatment until the end of the project
- • Patients who are unwilling to participate in the project or wish to withdraw from the research project
About Ramathibodi Hospital
Ramathibodi Hospital, a leading medical institution in Thailand, is renowned for its commitment to advancing healthcare through innovative research and clinical trials. Affiliated with Mahidol University, the hospital combines cutting-edge technology with expert clinical care, fostering an environment conducive to scientific inquiry and patient-centered research. With a focus on a wide array of medical disciplines, Ramathibodi Hospital aims to enhance treatment protocols and improve patient outcomes by actively participating in clinical trials that adhere to the highest ethical standards and regulatory compliance. Its collaborative approach involves multidisciplinary teams dedicated to exploring new therapeutic avenues and translating research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported